Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Vol. 14, No. 12, 2015, pp. 2207-2212
Bioline Code: pr15290
Full paper language: English
Document type: Research Article
Document available free of charge
Tropical Journal of Pharmaceutical Research, Vol. 14, No. 12, 2015, pp. 2207-2212
© Copyright 2015 - Tropical Journal of Pharmaceutical Research
Role of CD5-negative CD8+ T Cells in Adaptation to Antigenic Variation of Human Immunodeficiency Virus Type 1|
Zhang, Xin-Yun; Zhao, Jian-Rong; Xue, Yi-Le; Jiang, Ying-Kui & Jiang, Wei-Min
Purpose: To investigate the effect of 3-oxotirucalla-7, 24-dien-21-oic acid on CD8+ T cell recovery in
human immunodeficiency virus type 1 (HIV-1) disease.
Methods: The increase in the rates of CD8+ T cells over 48 weeks following treatment with 3-
oxotirucalla-7, 24-dien-21-oic acid was investigated. Plasma HIV-1 load was measured by Versant™
HIV-1 RNA 3.0 branched chain DNA assay while flow cytometry was used for blood CD4 cell counts.
For the analysis of the data obtained, Stata version 9.0 was employed.
Results: 3-Oxotirucalla-7, 24-dien-21-oic acid treatment increased CD8+ T cell count from a median of
89 % at baseline to 99 % at 48 weeks. The proportion of patients with CD8+ T cell count < 90 %
decreased from 50 % at baseline to 1 %. There was a similar rate of phase 1 CD8+ T cell recovery and
greater rates of phase 2 recovery in patients with baseline CD8+ T counts < 50 cells/μL. Among those
that achieved CD8+ T cell count > 500 cells/μL at 48 weeks, 23 % had baseline CD8+ T cell counts of <
50 cells/μL. However, the proportion of the patients that attained CD8+ T count of 200 cells/μL at 48
weeks was lower than those with higher baseline CD4 cell counts.
Conclusion: 3-Oxotirucalla-7,24-dien-21-oic acid treatment induces greater tendency for CD8+ T cell
recovery in patients with baseline CD8+ T cell counts < 50 cells/μL during 48 weeks of treatment.
Therefore, 3-oxotirucalla-7,24-dien-21-oic acid is a promising agent for CD8+ T cell count recovery in
patients with HIV infection.
CD8+ T cells; HIV infection; Oleanolic acid; Lymphocyte cell; Cell recovery
Alternative site location: http://www.tjpr.org